Seattle Genetics Highlights Data from Broad Oncology Portfolio During ESMO Virtual Congress 2020Business Wire • 08/27/20
Seattle Genetics Announces TUKYSA® (tucatinib) Approved Within Months for All Countries Participating in FDA’s Project Orbis InitiativeBusiness Wire • 08/12/20
Seattle Genetics Achieves Milestone Payment Under Antibody-Drug Conjugate Collaboration with GlaxoSmithKline Triggered by BLENREP (belantamab mafodotin-blmf) FDA ApprovalBusiness Wire • 08/06/20
Seattle Genetics, Inc. (SGEN) CEO Clay Siegall on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 07/31/20
Piper Sandler Downgrades Seattle Genetics, Says Visibility Limited On Value CreationBenzinga • 07/24/20
Goldman Sachs Sees Big Gains From 7 Biotech & Pharma Conviction Buy Stocks24/7 Wall Street • 07/24/20
Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2020 Financial Results on July 30, 2020Business Wire • 07/09/20
Teladoc, Dexcom, Vertex, Seattle Genetics, West Pharmaceutical: Five Medical Stocks In Or Near Buy ZonesInvestors Business Daily • 07/03/20
Seattle Genetics Announces Positive Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical CancerBusiness Wire • 06/29/20
Why Is Seattle Genetics (SGEN) Up 14.6% Since Last Earnings Report?Zacks Investment Research • 05/30/20
Seattle Genetics' (SGEN) CEO Clay Siegall on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/01/20